JPH0730114B2 - Inhibin - Google Patents

Inhibin

Info

Publication number
JPH0730114B2
JPH0730114B2 JP60069209A JP6920985A JPH0730114B2 JP H0730114 B2 JPH0730114 B2 JP H0730114B2 JP 60069209 A JP60069209 A JP 60069209A JP 6920985 A JP6920985 A JP 6920985A JP H0730114 B2 JPH0730114 B2 JP H0730114B2
Authority
JP
Japan
Prior art keywords
inhibin
molecular weight
treatment
sds
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60069209A
Other languages
Japanese (ja)
Other versions
JPS61229826A (en
Inventor
薫 宮本
喜久 長谷川
賢治 寒川
寿之 松尾
正雄 五十嵐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to JP60069209A priority Critical patent/JPH0730114B2/en
Publication of JPS61229826A publication Critical patent/JPS61229826A/en
Publication of JPH0730114B2 publication Critical patent/JPH0730114B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Description

【発明の詳細な説明】 〔産業上の利用分野〕 この発明は、インヒビン(INHIBIN)に関する。インヒ
ビンは、避妊薬としてあるいは畜産に利用できる性ホル
モンである。
DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to INHIBIN. Inhibin is a sex hormone that can be used as a contraceptive or in livestock production.

〔従来の技術〕[Conventional technology]

インヒビンは、Mc Cullagh(Science,76,19−20,(193
2))により去勢動物の下垂体に見られる去勢細胞の出
現を抑制する精巣の水溶性の抽出物として見い出され
た。卵巣性インヒビンとしてはDe Jongら(Nature,263,
71−72,(1976))によりウシの卵胞液中に見い出さ
れ、その後、ラット,ブタ,サル,ヒツジ,ウマ,ヒト
などの卵胞液中に多量のインヒビン活性が存在すること
が確かめられている。
Inhibin is Mc Cullagh (Science, 76 , 19-20, (193
2)) was found as a water-soluble extract of testis that suppresses the appearance of castrated cells found in the pituitary gland of castrated animals. As ovarian inhibin, De Jong et al. (Nature, 263 ,
71-72, (1976), found in bovine follicular fluid, and then confirmed that a large amount of inhibin activity is present in follicular fluid of rats, pigs, monkeys, sheep, horses, humans, etc. .

現在では、インヒビンは雌雄両性の性腺に存在する水溶
性の物質で、下垂体からのFSH(卵胞刺激ホルモン)の
合成,分泌を特異的に抑制する物質として考えられてい
る。インヒビンは卵胞の発育,成熟,排卵などの現象に
も関与していて視床下部下垂体性腺系で生殖生理上、重
要な役割を果している。
At present, inhibin is a water-soluble substance that exists in both sexes, and is considered to be a substance that specifically suppresses the synthesis and secretion of FSH (follicle-stimulating hormone) from the pituitary gland. Inhibin is also involved in phenomena such as follicle development, maturation, and ovulation, and plays an important role in reproductive physiology in the hypothalamic pituitary gland system.

卵巣性インヒビンの内、ブタのものについてWilliamら
(Partial Purification of Porcine Follcular Fluid
Gonadostatin,Intraovarian Control Mechanisms,Advan
ces Experimental Medicine and Biology,vol.147,Plen
um Press,New York,99−116,1982)はブタ卵胞液の「セ
ファクリルS−300」によるゲル濾過クロマトグラフィ
ーの溶出液中分子量26,000の画分にインヒビン活性があ
ることを見い出している。しかるに、この文献において
は、インヒビンは精製されておらず、従って、インヒビ
ン活性は単一の物質によって発現されるのか、あるいは
インヒビン活性を有する複数の物質が存在するのかは明
らかにされていない。現に我々の研究によれば、ブタ卵
胞液中には分子量3万近辺のものに限っても、少くとも
3種のインヒビン活性を有する物質が見い出されてい
る。
Of the ovarian inhibins, pigs were described by William et al. (Partial Purification of Porcine Follcular Fluid
Gonadostatin, Intraovarian Control Mechanisms, Advan
ces Experimental Medicine and Biology, vol.147, Plen
Um Press, New York, 99-116, 1982) found that the fraction with a molecular weight of 26,000 in the eluate of gel filtration chromatography with "Sephacryl S-300" of porcine follicular fluid had inhibin activity. However, in this document, inhibin has not been purified, and therefore it is not clarified whether inhibin activity is expressed by a single substance or whether there are multiple substances having inhibin activity. In fact, according to our research, at least three kinds of substances having inhibin activity have been found in porcine follicular fluid, even if it has a molecular weight of around 30,000.

〔本発明が解決しようとする問題点〕[Problems to be Solved by the Present Invention]

叙上のように、従来インヒビンは単一の物としては分離
されていないため、その特異な生理活性からして避妊薬
等に使用できる大きな可能性があるにも拘らず、その応
用はできなかった。従って、この発明の目的はインヒビ
ンを単一の物質として得ることにある。
As mentioned above, since inhibin has not been isolated as a single substance in the past, its application is not possible despite its great potential to be used as a contraceptive due to its unique physiological activity. It was Therefore, an object of the present invention is to obtain inhibin as a single substance.

〔問題点を解決するための手段〕[Means for solving problems]

本発明者らは、ブタの卵胞液よりインヒビンを単一物質
として分離,精製し、その物理的,化学的性質を明らか
にすることに成功した。
The present inventors succeeded in separating and purifying inhibin as a single substance from porcine follicular fluid and clarifying its physical and chemical properties.

この発明の32Kインヒビン−IIと名付けられたインヒビ
ンは、以下の性質を有するものである。
The inhibin named 32K inhibin-II of the present invention has the following properties.

(a)分子量:32kd(SDS−ゲル電気泳動法及び高速液体
クロマトグラフィー法) (b)還元により分子量20kdと13kd(SDS−ゲル電気泳
動法)のポリペプチドが生じ、活性を失う。
(A) Molecular weight: 32 kd (SDS-gel electrophoresis method and high performance liquid chromatography method) (b) Reduction produces polypeptides with molecular weights of 20 kd and 13 kd (SDS-gel electrophoresis method), which loses activity.

(c)コンカナバリンAセファロースカラムに吸着さ
れ、α−メチルマンノシドによって溶出される。
(C) Adsorbed on a concanavalin A sepharose column and eluted with α-methyl mannoside.

(d)等電点:p16付近 (e)プロテアーゼ処理により失活し、ノイラミニダー
ゼ処理及びエンドグリコシダーゼH処理により失活しな
い。
(D) Isoelectric point: around p16 (e) Inactivated by protease treatment, but not by neuraminidase treatment and endoglycosidase H treatment.

(f)N−末端アミノ酸配列: 分子量20×103のポリペプチド: Ser Thr 分子量13×103のポリペプチド: Gly Leu (g)ブタ卵胞液中に存在し、卵胞刺激ホルモンの上昇
を抑制する。
(F) N-terminal amino acid sequence: Polypeptide having a molecular weight of 20 × 10 3 : Ser Thr Polypeptide having a molecular weight of 13 × 10 3 : Gly Leu (g) Exists in porcine follicular fluid and suppresses elevation of follicle-stimulating hormone .

本発明のインヒビンは、例えば以下の方法で得ることが
できる。
The inhibin of the present invention can be obtained, for example, by the following method.

ブタ卵巣を集め、卵胞液を吸引等により採取する。イン
ヒビンは、「マトリックス ゲル レッドA」(アミコ
ン社)に特異的に吸着されるので(Molecular and Cell
ular Endocrinology,21,109−117,(1981))、まず、
このゲルによるマフィニティ−クロマトグラフィーを行
う。
Collect pig ovaries and collect follicular fluid by suction or the like. Inhibin is specifically adsorbed on "Matrix Gel Red A" (Amicon) (Molecular and Cell).
ular Endocrinology, 21 , 109-117, (1981)), first,
Maffinity chromatography on this gel is performed.

ついで本発明者らの研究によれば、「フェニルセファロ
ース」,「セファクリル S−200」,「DEAE セファ
クリル CL6B」によるクロマトグラフィー及び最後に逆
相高速液体クロマトグラフィーによる精製がこの物質の
精製には最も適している。これらのクロマトグラフィー
における溶離溶媒としては8Mウレアが最適である。
Then, according to the research conducted by the present inventors, chromatography by "phenyl sepharose", "Sephacryl S-200", "DEAE Sephacryl CL6B" and finally purification by reverse phase high performance liquid chromatography were the most suitable for the purification of this substance. Are suitable. 8M urea is the most suitable eluent in these chromatography.

インヒビンの活性は、以下のようにして測定することが
できる。
The activity of inhibin can be measured as follows.

(1)ラット下垂体前葉細胞培養法 ラット下垂体前葉をトリプシン及びビオカーゼにより分
散し、細胞濃度5〜8万個/0.1ml/ウエルとなるように
プラスチックプレートに入れる。各ウエルにインヒビン
検体0.1mlを加え、37℃に10%炭酸ガスを含む空気中に
て72時間保つ。培地はDMEMに5%ヒト臍帯血清,2.5%FC
S,5%馬血清を加えたものを用いる。活性は培地中に放
出されたFSH含量をラジオイムノアッセイにより測定し
て、FSH放出の抑制度で以って表わす。32Kインヒビン−
IIは、ED50=1.2ng/ml−培地の活性を持つ。
(1) Rat pituitary anterior pituitary cell culture method The rat anterior pituitary is dispersed with trypsin and biocase and placed in a plastic plate so that the cell concentration is 50,000 / 0.1 ml / well. Add 0.1 ml of inhibin sample to each well and keep at 37 ° C in air containing 10% carbon dioxide gas for 72 hours. The medium is DMEM, 5% human umbilical cord serum, 2.5% FC
Use S, 5% horse serum added. The activity is expressed by the degree of inhibition of FSH release measured by radioimmunoassay for the FSH content released in the medium. 32K inhibin
II has an activity of ED 50 = 1.2 ng / ml-medium.

(2)生体内試験法 35日令の雄ラットを去勢し、去勢後6から24時間にかけ
て上昇してくる血中FSHをラジオイムノアッセイにて測
定する。インヒビン検体は、去勢と同時に腹腔内投与
し、9時間後の血中FSH値の上昇に対する抑制程度を測
定する。この方法では(1)の方法に比べ約5,000倍の
検体量を必要とする。
(2) In vivo test method Male rats aged 35 days are castrated, and blood FSH rising from 6 to 24 hours after castration is measured by radioimmunoassay. The inhibin sample is intraperitoneally administered at the same time as castration, and the degree of suppression of the increase in blood FSH level after 9 hours is measured. This method requires about 5,000 times the amount of sample as compared with the method (1).

〔本発明の作用,効果〕[Operation and effect of the present invention]

本発明の卵巣性インヒビンは、ヒトの避妊薬として用い
られる他、家畜の妊娠時期を揃える等畜産に応用でき
る。
The ovarian inhibin of the present invention is used as a contraceptive agent for humans and can be applied to livestock production such as aligning the pregnancy period of livestock.

〔実施例〕〔Example〕

(1)インヒビンの分離,精製 ブタ卵巣より吸引により卵細胞を採取し、10,000rpm,1
時間の遠心により上澄液を集めた。この上澄液に2倍容
の50mMトリス−塩酸緩衝液(pH7.5)を加え、同じ緩衝
液により緩衝化された「マトリックスゲル レッドA」
カラム(8.0×25cm)にのせ、ついで上記緩衝液に0.15M
KClを加えた溶液で充分洗浄後、上記緩衝液に1.0M尿素
と1.2M KClを加えた溶液で溶出した。
(1) Separation and purification of inhibin Egg cells were collected from the ovary of pigs by suction, 10,000 rpm, 1
The supernatant was collected by centrifugation for an hour. To this supernatant was added 2 volumes of 50 mM Tris-hydrochloric acid buffer (pH 7.5) and buffered with the same buffer as "matrix gel red A".
Place on a column (8.0 x 25 cm), then add 0.15 M to the above buffer
After thoroughly washing with a solution containing KCl, elution was carried out with a solution containing 1.0 M urea and 1.2 M KCl added to the above buffer solution.

得られた溶出液に1/4容の2M KClを加え、「フェニルセ
ファロース」カラム(2.5×30cm)にのせ、50mMトリス
塩酸緩衝液(pH7.5)に1M KClを加えた緩衝液で充分洗
浄後、50mMトリス塩酸緩衝液(pH7.5)に8M尿素を加え
た溶液で溶出した。
To the obtained eluate, add 1/4 volume of 2M KCl, put it on a "Phenyl Sepharose" column (2.5 x 30 cm), and wash thoroughly with 50 mM Tris-HCl buffer (pH 7.5) containing 1 M KCl. After that, elution was carried out with a solution containing 8 mM urea in 50 mM Tris-HCl buffer (pH 7.5).

溶出液を、「セファクリル S−200」カラムを用いて
ゲル濾過クロマトグラフィーを行った。展開緩衝液とし
て8M尿素を含むトリス塩酸緩衝液を用いた。これにより
分子量約8万と約3万の位置にインヒビン活性が認めら
れた。分子量3万の分画を集め、「DEAE−セファロース
CL6B」カラム(1.5×30cm)を用いてイオン交換クロ
マトグラフィーを行った。インヒビン活性は3個所に分
れて溶出され、第二のピークが最も活性が強かった(第
1図)。
The eluate was subjected to gel filtration chromatography using a "Sephacryl S-200" column. Tris-hydrochloric acid buffer containing 8 M urea was used as a development buffer. As a result, inhibin activity was recognized at positions of molecular weights of about 80,000 and about 30,000. Fractions with a molecular weight of 30,000 were collected, and "DEAE-Sepharose
Ion exchange chromatography was performed using a "CL6B" column (1.5 x 30 cm). The inhibin activity was separated and eluted at three sites, and the second peak had the strongest activity (Fig. 1).

上記第二のピークの分画を集め、下記のように逆相高速
液体クロマトグラフィーを行った。インヒビン−IIはア
セトニトリル濃度34%の位置に単一ピークとして溶出さ
れた。
Fractions of the second peak were collected and subjected to reverse phase high performance liquid chromatography as described below. Inhibin-II was eluted as a single peak at the position where the concentration of acetonitrile was 34%.

カラム:「TSK−120T」,4.0×150mm,溶出:(A)10%
トリフルオル酢酸(TFA):アセトニトリル:水=1:10:
90,(B)10%TFA:アセトニトリル:水=1:60:40による
直線グラジェント。
Column: "TSK-120T", 4.0 x 150 mm, elution: (A) 10%
Trifluoroacetic acid (TFA): acetonitrile: water = 1: 10:
90, (B) 10% TFA: acetonitrile: water = 1: 60: 40 linear gradient.

以上の精製工程における蛋白量,インヒビン活性等の変
化は第1表に示すとおりである。
The changes in the amount of protein, inhibin activity and the like in the above purification steps are as shown in Table 1.

得られた標品は、再逆相高速液体クロマトグラフィー,S
DS−ゲル電気泳動により単一であり、そのインヒビン活
性は卵胞液と比較して約5,000倍になっていた。卵細胞
1あたり約0.7mgの精製標品が得られた。
The obtained standard was re-reversed phase high performance liquid chromatography, S
It was single by DS-gel electrophoresis, and its inhibin activity was about 5,000 times higher than that of follicular fluid. About 0.7 mg of purified preparation was obtained per egg cell.

(2)32Kインヒビン−IIの物性 (a)逆相高速液体ゲル濾過クロマトグラフィー(カラ
ムTSK−3000SW)による分子量は32kdである。
(2) Physical properties of 32K inhibin-II (a) The molecular weight by reverse phase high performance liquid gel filtration chromatography (column TSK-3000SW) is 32 kd.

(b)SDS−ゲル電気泳動による分子量は、32kdであ
る。
(B) The molecular weight by SDS-gel electrophoresis is 32 kd.

(c)還元剤,酸化剤により容易に失活し、SDS−ゲル
電気泳動で分子量約20kdと約13kdの2つのポリペプチド
が生じる。
(C) It is easily inactivated by a reducing agent and an oxidizing agent, and two polypeptides having a molecular weight of about 20 kd and about 13 kd are produced by SDS-gel electrophoresis.

(d)上記ポリペプチドのN−末端アミノ酸は20kdのも
のはSer The Ala Pro,13kdのものはGly Leu Gln Cysで
あった。
(D) The N-terminal amino acid of the above polypeptide was Ser The Ala Pro with 20 kd and Gly Leu Gln Cys with 13 kd.

(e)32Kインヒビン−IIは、コンカナバリンAセファ
ロースカラムに吸着され、α−メチルマンノシドによっ
て溶出されるので、糖蛋白質である。
(E) 32K inhibin-II is a glycoprotein because it is adsorbed on a concanavalin A sepharose column and eluted with α-methylmannoside.

(f)32Kインヒビン−IIは、プロテアーゼ処理によっ
て失活する(トリプシンにて60%,ペプシンにて85%,
キモトリプシンにて70%,プロナーゼにて95%,サーモ
ライシンにて98%失活する。)。
(F) 32K inhibin-II is inactivated by protease treatment (trypsin 60%, pepsin 85%,
It is inactivated by 70% by chymotrypsin, 95% by pronase, and 98% by thermolysin. ).

(g)32Kインヒビン−IIは、イノラミニダーゼ処理,
エンドグリコシダーゼH処理によっては失活しない。
(G) 32K inhibin-II was treated with inoraminidase,
It is not inactivated by treatment with endoglycosidase H.

(h)等電点:p16付近 (H) Isoelectric point: around p16

【図面の簡単な説明】[Brief description of drawings]

第1図は32Kインヒビン−IIのイオン交換クロマトグラ
フィーの溶出パターンである。
FIG. 1 shows the elution pattern of 32K inhibin-II by ion exchange chromatography.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 寒川 賢治 宮崎県宮崎郡清武町加納甲1520―24 (72)発明者 松尾 寿之 宮崎県宮崎郡清武町木原6653A―104 (72)発明者 五十嵐 正雄 群馬県前橋市日吉町4丁目357―4 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Kenji Samukawa 1520-24 Kano Ko, Kiyotake-cho, Miyazaki-gun, Miyazaki Prefecture (72) Inventor Toshiyuki Matsuo 6653A-104 Kihara, Kiyotake-cho, Miyazaki-gun, Miyazaki Prefecture (72) Masao Igarashi Gunma Gunma 357-4, 4-chome, Hiyoshi-cho, Maebashi, Japan

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】以下の性質を有するインヒビン。 (a)分子量:32kd(SDS−ゲル電気泳動法及び高速液体
クロマトグラフィー法) (b)還元により分子量20kdと13kd(SDS−ゲル電気泳
動法)のポリペプチドが生じ、活性を失う。 (c)コンカナバリンAセファロースカラムに吸着さ
れ、α−メチルマンノシドによって溶出される。 (d)等電点:p16付近 (e)プロテアーゼ処理により失活し、ノイラミニダー
ゼ処理及びエンドグリコシダーゼH処理により失活しな
い。 (f)N−末端アミノ酸配列: 分子量20×103のポリペプチド: Ser Thr 分子量13×103のポリペプチド: Gly Leu (g)ブタ卵胞液中に存在し、卵胞刺激ホルモンの上昇
を抑制する。
1. Inhibin having the following properties. (A) Molecular weight: 32 kd (SDS-gel electrophoresis method and high performance liquid chromatography method) (b) Reduction produces polypeptides with molecular weights of 20 kd and 13 kd (SDS-gel electrophoresis method), which loses activity. (C) Adsorbed on a concanavalin A sepharose column and eluted with α-methyl mannoside. (D) Isoelectric point: around p16 (e) Inactivated by protease treatment, but not by neuraminidase treatment and endoglycosidase H treatment. (F) N-terminal amino acid sequence: Polypeptide having a molecular weight of 20 × 10 3 : Ser Thr Polypeptide having a molecular weight of 13 × 10 3 : Gly Leu (g) Exists in porcine follicular fluid and suppresses elevation of follicle-stimulating hormone .
JP60069209A 1985-04-03 1985-04-03 Inhibin Expired - Lifetime JPH0730114B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP60069209A JPH0730114B2 (en) 1985-04-03 1985-04-03 Inhibin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60069209A JPH0730114B2 (en) 1985-04-03 1985-04-03 Inhibin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP23863394A Division JPH07238097A (en) 1994-09-07 1994-09-07 Igg antibody comprising inhibin as antigen

Publications (2)

Publication Number Publication Date
JPS61229826A JPS61229826A (en) 1986-10-14
JPH0730114B2 true JPH0730114B2 (en) 1995-04-05

Family

ID=13396101

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60069209A Expired - Lifetime JPH0730114B2 (en) 1985-04-03 1985-04-03 Inhibin

Country Status (1)

Country Link
JP (1) JPH0730114B2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2652534B2 (en) * 1985-04-18 1997-09-10 バイオテクノロジー・オーストラリア・ピーテイーワイ・リミテツド Recombinant inhibin
EP0218717B1 (en) * 1985-04-18 1998-07-15 Biotechnology Australia Pty. Ltd. Recombinant inhibin
US4740587A (en) * 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
US5089396A (en) * 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
JPS63119679A (en) * 1985-10-03 1988-05-24 ジエネンテク,インコ−ポレイテツド Nucleic acid encoding alpha chain and beta chain of inhibin and synthesis of polypeptide using the same
US4997815A (en) * 1988-11-01 1991-03-05 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
US5942220A (en) * 1990-03-16 1999-08-24 Chiron Corporation Inhibitor of cytokine activity and applications thereof

Also Published As

Publication number Publication date
JPS61229826A (en) 1986-10-14

Similar Documents

Publication Publication Date Title
Duckworth et al. Purification of insulin-specific protease by affinity chromatography
Buus et al. Autologous peptides constitutively occupy the antigen binding site on Ia
Aggarwal et al. Human tumor necrosis factor. Production, purification, and characterization.
Bridgen et al. Photoreceptor protein from the purple membrane of Halobacterium halobium. Molecular weight and retinal binding site
PIERCE et al. Studies on the structure of thyrotropin: its relationship to luteinizing hormone
Elliott et al. Methionyl-lysyl-bradykinin, a new kinin from ox blood
EP0128849B1 (en) Purified transforming growth factor-beta derived from human platelets and placentas
JPH0764875B2 (en) Novel polypeptide having anticoagulant effect
Jones et al. Large-scale preparation of highly purified pyrogen-free human growth hormone for clinical use
JPH07108916B2 (en) Inhibin and its purification method
Dixit et al. Isolation and characterization of pepsin solubilized basement membrane collagens (type IV) from human placenta, bovine kidney cortices, and bovine lens capsule
Fernley et al. Purification and characterization of a high-M r carbonic anhydrase from sheep parotid gland
Rosenstreich et al. A human urine-derived interleukin 1 inhibitor. Homology with deoxyribonuclease I.
JPH0730114B2 (en) Inhibin
JPH01308300A (en) Heparine bondable brain mitogen
Sano et al. Saposin-C from bovine spleen; complete amino acid sequence and relation between the structure and its biological activity
US7485622B2 (en) Paralytic peptide for use in neuromuscular therapy
US3903069A (en) Polypeptides obtained by modification of porcine or bovine insulin
Bosc-Bierne et al. Isolation and partial structural characterization of chicken pancreatic colipase
Green et al. The purification and properties of a single chicken pepsinogen fraction and the pepsin derived from it
JP3030312B2 (en) Mature hepatocyte growth factor (I)
US3119740A (en) Process for preparing purified follicle stimulating hormone
JP3251545B2 (en) Sperm motility promoting high molecular protein
JPH07238097A (en) Igg antibody comprising inhibin as antigen
Tamura-Takahashi et al. Purification and properties of four biologically active components of whale luteinizing hormone